FG
Francisco Gimeno Valiente
INCLIVA Health Research Institute, University College London, Universitat de València, Fundación Instituto Valenciano de Oncología
Research areas: Medicine · Oncology · Cancer Genomics and Diagnostics · Colorectal Cancer Treatments and Studies · Genetic factors in colorectal cancer
0000-0003-0544-9459
Employment
-
INCLIVA Health Research Institute Senior Postdoctoral Researcher2024 - Present
-
University College London Postdoctoral Researcher2024 - 2024
-
University College London Postdoctoral Researcher2019 - 2023
-
INCLIVA Health Research Institute PhD student contract2017 - 2020
-
INCLIVA Health Research Institute Student intern2016 - 2016
-
Fundación Instituto Valenciano de Oncología Student intern2014 - 2014
Education
-
University of Valencia PhD program in biotechnology and biomedicine? - 2019
-
University of Valencia Master degree in molecular biology, cell and genetics research? - 2016
-
University of Valencia Degree in biology, mention in health biology? - 2015
Projects & Funding
-
Validation of PROMISE: A Prediction of Recurrence Outcome via Methylation Signature in Lung Cancer CRUK City of London Centre Development Fund2025 - 2026
Publications (50)
- Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer Save
- Subclonal immune evasion in non-small cell lung cancer Save
- DNA methylation cooperates with genomic alterations during non-small cell lung cancer evolution Save
- A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer Save
- Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer Save
- ImmuneLENS characterizes systemic immune dysregulation in aging and cancer Save
- Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy Save
- Decoding chromosomal instability insights in CRC by integrating omics and patient-derived organoids Save
- Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma Save
- TRACERx analysis identifies a role for FAT1 in regulating chromosomal instability and whole-genome doubling via Hippo signalling Save
- Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma Save
- Method for monitoring cancer using minimal residual disease analysis. Save
- MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution Save
- ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients Save
- Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling Save
- The Many Roads from Alternative Splicing to Cancer: Molecular Mechanisms Involving Driver Genes Save
- Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models Save
- The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma Save
- The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance Save
- Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer Save